黄斑变性讲座（精品）ppt课件_1.pptVIP

State-of-the-Science:Treatment of NeovascularAge-Related Macular Degeneration (AMD) ;Presentation Outline;Overview of Age-Related Macular Degeneration (AMD);Definition;Epidemiology;Projected Prevalence of Advanced AMD* in the United States;Photoreceptors;Normal retina;New abnormal blood vessels proliferate and penetrate Bruch’s membrane;Advanced Wet AMDFibrovascular Scar;Current Therapies in the Treatment of Neovascular AMD;Thermal effects of laser destroys CNV, low recurrence rate Causes damage to surrounding healthy tissue Not for use on CNV located beneath fovea (subfoveal) Immediate, permanent decrease in central vision;Verteporfin;Forms of SubfovealNeovascular AMD;6;Endothelial cell activation, proliferation, migration4;Multiple Isoforms of VEGF-A Are Generated from Exon Splicing;VEGF Inhibition in AMD;Pegaptanib for Neovascular AMDThe VISION Study;68%;Two Pivotal Phase III Ranibizumab Trials in Neovascular AMD;MARINA Trial: Primary EndpointPatients Losing 15 Letters from Baseline at Month 12;Secondary Endpoint:Mean Change in Visual Acuity Over Time;ANCHOR Trial: Primary EndpointSubjects Losing 15 Letters from Baseline at Month 12;ETDRS Letters;Investigational Bevacizumab Trials;Summary;Summary;Implications of Anti-VEGFTherapies in Managed Care:Avoiding Billing Pitfalls;;CAP;Under CAP;Under CAP;Why Would Physicians Choose CAP?1;Experience with Commercial CAP;Experience with Buy and Bill1;Analyze Past Experience;Patient Population for AMD;Importance of ABNs;Sample AMD Coverage Matrix;Successful Billing Basics;Financial Good Housekeeping;AMD Treatment Collections;Collections by Treatment Type;Patient Cost Education;Manufacturer Resources;Insurance Carriers;Implications of Anti-VEGF Therapies in Managed Care: Reimbursement Strategies;Intravitreal Injection Reimbursement;Top 10 Ophthalmic ProceduresMedicare Utilization Patterns (18 - Ophthalmology);Medicare Utilization ;Part B Growth in Services;Intravitreal Injection Reimbursement;Medicare Reimburse